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Research
Obesity, insulin resistance, and type 2 diabetes
are interrelated metabolic disorders whose
prevalence has increased substantially in the
past two decades. Corresponding increases in
premature morbidity and mortality are
expected (Adams et al. 2006; Fujimoto 2000;
Haffner et al. 1998; Poirier et al. 2006;
Zimmet et al. 2001). Insulin resistance occurs
when increasing amounts of insulin are
required to correctly regulate transport of
plasma glucose into peripheral tissues.
Although the precise mechanism is unclear,
insulin resistance is commonly accompanied
by central (visceral) obesity, which, by elevat-
ing levels of free fatty acids in serum, may pro-
voke insulin resistance and disrupt lipid
metabolism. Initially, the beta cells of the pan-
creas can fully compensate for mild insulin
resistance by increasing insulin production. As
the disease progresses, beta cells decompen-
sate, resulting in elevated serum glucose levels
and the subsequent development of type 2
diabetes. 
Testosterone affects body fat distribution
and insulin sensitivity in men. Experimental
studies in males have shown that testosterone
administration reduces lipid uptake by intra-
abdominal fat (Mårin et al. 1996) and also
reduces visceral fat and improves insulin sensi-
tivity (Mårin 1995; Mårin et al. 1992, 1993).
A 2005 meta-analysis found that testosterone
administration reduces total fat mass (Isidori
et al. 2005). Men undergoing androgen depri-
vation therapy for prostate cancer have
increased serum glucose, total fat, and preva-
lence of metabolic syndrome (Braga-Basaria
et al. 2006; Shariﬁ et al. 2005). Epidemiologic
studies often support these findings (Ding
et al. 2006; Selvin et al. 2007), but sometimes
they do not (Oh et al. 2002). 
Humans are commonly exposed to man-
made chemicals that have the potential to
reduce androgen (e.g., testosterone) produc-
tion or function. One such class of chemicals
is phthalates, which are used in a variety of
products, including cosmetics, shampoos,
soaps, lubricants, pesticides, and paints; it is
also used as a softener of polyvinyl chloride.
More than 75% of the U.S. population has
measurable levels of several phthalate metabo-
lites in the urine (Silva et al. 2004). Unlike
polychlorinated biphenyls (PCBs) and dioxins,
phthalates are quickly metabolized and
excreted (Hauser and Calafat 2005). The half-
life of di(2-ethylhexyl)phthalate (DEHP), one
of the most widely used and studied phtha-
lates, is < 24 hr (Koch et al. 2004).
Phthalates are known antiandrogens in
experimental animal models, with consistent
results dating back several decades. Testicular
steroid hormone synthesis and reproductive
system development in males have been
adversely affected by exposure, especially
neonatal exposure, to certain phthalates,
including DEHP, di-butyl phthalate (DBP),
benzyl-butyl phthalate, and di-isononyl phtha-
late (Bell 1982; Fisher 2004; Parks et al. 2000).
Associations between certain phthalate
metabolites and antiandrogenic effects have
also been found in humans at much lower
exposure levels than those used in rodent
experiments. Suspected metabolites include
mono-benzyl phthalate (MBzP), mono-ethyl
phthalate (MEP), mono-isononyl phthalate
(MiNP), mono-methyl phthalate, and mono-
butyl phthalate (MBP). Urinary phthalate
metabolites in pregnant women have been
found to correlate with subtle genital changes
in their infant males (Swan et al. 2005), and
breast-milk phthalate metabolites have been
correlated with shifts in reproductive hor-
mones in infant males (Main et al. 2006).
Although fetuses and infants are thought
to be more susceptible to environmental
insult than adults, Duty et al. (2003) and
Hauser et al. (2006) found diminished sperm
quality associated with urinary phthalate
metabolites in adult males as well. If their
ﬁndings reﬂect true antiandrogenic effects of
phthalates or their metabolites at current
exposure levels, then one may reasonably pre-
dict that these exposures could increase the
prevalence of metabolic disorders that are
worsened by diminished androgen production
or function. 
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BACKGROUND: Phthalates impair rodent testicular function and have been associated with anti-
androgenic effects in humans, including decreased testosterone levels. Low testosterone in adult
human males has been associated with increased prevalence of obesity, insulin resistance, and diabetes. 
OBJECTIVES: Our objective in this study was to investigate phthalate exposure and its associations
with abdominal obesity and insulin resistance. 
METHODS: Subjects were adult U.S. male participants in the National Health and Nutrition
Examination Survey (NHANES) 1999–2002. We modeled six phthalate metabolites with prevalent
exposure and known or suspected antiandrogenic activity as predictors of waist circumference and
log-transformed homeostatic model assessment (HOMA; a measure of insulin resistance) using
multiple linear regression, adjusted for age, race/ethnicity, fat and total calorie consumption, physical
activity level, serum cotinine, and urine creatinine (model 1); and adjusted for model 1 covariates
plus measures of renal and hepatic function (model 2). Metabolites were mono-butyl phthalates
(MBP), mono-ethyl phthalate (MEP), mono-(2-ethyl)-hexyl phthalate (MEHP), mono-benzyl
phthalate (MBzP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono-(2-ethyl-5-
oxohexyl) phthalate (MEOHP). 
RESULTS: In model 1, four metabolites were associated with increased waist circumference (MBzP,
MEHHP, MEOHP, and MEP; p-values ≤ 0.013) and three with increased HOMA (MBP, MBzP,
and MEP; p-values ≤ 0.011). When we also adjusted for renal and hepatic function, parameter
estimates declined but all signiﬁcant results remained so except HOMA-MBP. 
CONCLUSIONS: In this national cross-section of U.S. men, concentrations of several prevalent
phthalate metabolites showed statistically significant correlations with abdominal obesity and
insulin resistance. If conﬁrmed by longitudinal studies, our ﬁndings would suggest that exposure to
these phthalates may contribute to the population burden of obesity, insulin resistance, and related
clinical disorders.
KEY WORDS: androgens, homeostatic model assessment, insulin resistance, obesity, phthalates.
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[Online 14 March 2007]In this study we examined the association
between phthalate exposure and two key
metabolic abnormalities associated with hypo-
androgenism: abdominal obesity and insulin
resistance. Although these conditions are
closely related, they represent key precursors—
alone or in combination—to the development
of type 2 diabetes and cardiovascular disease
(Janssen et al. 2004; Reaven 1988). Our
hypothesis was that increased phthalate expo-
sure would be associated with increased
abdominal obesity and insulin resistance.
Methods
Study population. We used data from the
1999–2002 National Health and Nutrition
Examination Survey (NHANES) for this
analysis. NHANES, conducted by the
National Center for Health Statistics (NCHS),
Centers for Disease Control and Prevention
(CDC), is a multistage, stratified, clustered
design that selects a representative sample of
the civilian, noninstitutionalized U.S. popula-
tion. Certain subgroups, such as older adults,
Mexican Americans, non-Hispanic blacks, and
low-income persons, were sampled at a higher
rate than other demographic groups, thus
necessitating the use of sample weights in
analysis. Data from NHANES subjects are
acquired through household interviews and
standardized examinations at mobile examina-
tion centers throughout the United States.
Detailed methods have been published else-
where (NCHS 2006b).
We limited our analysis to men > 18 years
of age with complete data for the measures
described below. Men on insulin, oral hypo-
glycemic agents, or sex hormone agonists/
antagonists were excluded because these
medications may affect the biological mecha-
nisms of interest. Men were also excluded
from the insulin resistance analyses if they
reported to NCHS that they failed to fast for
8–24 hr before collection of fasting blood
samples.
In NHANES 1999–2002, a random one-
third subsample was selected for urinary
phthalate metabolite measurements, and a
separate random, but overlapping, one-third
subsample was selected for fasting glucose and
insulin (used to compute insulin resistance)
measurements. Of the 5,094 adult men avail-
able in NHANES, 1,451 men had both
phthalate and obesity measurements for crude
analyses after exclusions. Of these men, 45%
(n = 651) also had fasting measurements.
Two of the phthalate metabolites, mono-(2-
ethyl-5-hydroxyhexyl) phthalate (MEHHP)
and mono-(2-ethyl-5-oxohexyl) phthalate
(MEOHP), were only available for the years
2001–2002, reducing sample size for these
metabolites by about half (waist circumfer-
ence, n = 781; insulin resistance, n = 344).
Missing data reduced sample sizes for fully
adjusted models (vs. crude) by 11% for waist
circumference and 4.5% for insulin resistance. 
Abdominal obesity. Waist circumference
was chosen as the best available measure of
abdominal obesity. As a predictor of insulin
resistance, waist circumference has been
found to be an equivalent and, in some cases,
a better measure than body mass index (Farin
et al. 2006; Janssen et al. 2004). Waist cir-
cumference was measured at the high point of
the iliac crest at minimal respiration to the
nearest 1 mm. 
Insulin resistance. We estimated insulin
resistance using HOMA (homeostatic model
assessment). HOMA is epidemiologically
practical, widely used, and correlates accept-
ably (R = 0.73–0.88) with the hyperinsuline-
mic-euglycemic clamp test, which is generally
considered to be the gold standard (Matthews
et al. 1985; Wallace et al. 2004). HOMA was
calculated from fasting plasma glucose and
insulin measures following the method of
Matthews et al. (1985):
HOMA = [fasting insulin (μU/mL) 
× fasting glucose (mmol/L)]/22.5. [1]
Plasma glucose was determined by an enzy-
matic reaction (Cobas Miras assay); plasma
insulin was determined using a radio-
immunoassay with the double-antibody batch
method. 
Phthalate exposure. Phthalate data were
collected in NHANES as urinary metabo-
lites—rather than unmetabolized phthalates
in serum—to eliminate contamination dur-
ing collection and analysis (Latini 2005).
Laboratory methods have been previously
described (Silva et al. 2004). Seven metabo-
lites were measured throughout the 4-year
period, with five additional metabolites
measured in 2001–2002 subjects only. For
measurements below the limit of detection
(LOD), the NCHS assigned a default value
of LOD divided by the square root of 2, a
method of handling nondetectable values
that produces reasonably nonbiased means
and SDs (Hornung and Reed 1990).
Of the seven phthalates with data for all
4 years, four (MBP, MEP, MiNP, MBP) are
suspected human antiandrogens based on exist-
ing human studies (Duty et al. 2003; Hauser
et al. 2006; Main et al. 2006; Swan et al. 2005).
Metabolites of DEHP, the most widely studied
antiandrogenic phthalate, were also of interest:
mono(2-ethylhexyl) phthalate (MEHP) because
it was available for all 4 years, and MEHHP
and MEOHP (2001–2002 only) because sec-
ondary DEHP metabolites are suspected to be
more biologically active (Koch et al. 2005;
Stroheker et al. 2005). MiNP was eliminated
from further consideration because its concen-
tration was < LOD in > 75% of subjects. In
NHANES 1999–2000, MBP represented both
mono-n-butyl phthalate and mono-isobutyl
phthalate, whereas in NHANES 2001–2002,
these metabolites were measured separately
(CDC 2005). In the present study, we
summed the two mono-butyl phthalate
metabolites in 2001–2002 data to permit
analyses of mono-butyl phthalates over the
4-year period.
Potential confounders. Covariates included
in our analyses were age, race/ethnicity, family
history of diabetes, dietary fat and caloric
intake, physical activity, income, renal func-
tion, hepatic function, and exposure to
tobacco smoke. Race/ethnicity was self-identi-
fied (white, black, Mexican American, other
Hispanic, and other/multiethnic). Family his-
tory of diabetes was dichotomous (yes, no).
Total dietary fat (continuous) and caloric
intake (continuous) were computed from a
24-hr recall dietary questionnaire. Two physi-
cal activity measures were included: moderate
to vigorous leisure activity (continuous; meta-
bolic equivalents/month) and video-based
(computer, video, TV) inactivity (categorical,
hours/day: 0, < 1, 1, 2, 3, 4, ≥ 5). Socio-
economic status was represented as a “poverty
income ratio,” a measure of income relative to
family size and compared to the federal
poverty threshold (categorical, percentage of
poverty threshold: < 100, 100–199, 200–299,
300–399, 400–499, > 500). The renal func-
tion measure was glomerular filtration rate
(GFR; continuous), estimated using the four-
variable equation from the Modification of
Diet in Renal Disease study (Levey et al.
1999), incorporating serum creatinine adjust-
ments per NCHS instructions (NCHS
2006c). Liver function was represented by ala-
nine aminotransferase (ALT; continuous) and
gamma glutamyl transferase (GGT; continu-
ous). Exposure to tobacco smoke was deter-
mined using serum cotinine (continuous).
Statistical analysis. For descriptive analy-
ses, we computed median and mean phthalate
metabolite levels, adjusting for urine concen-
tration by dividing metabolite measurements
by urine creatinine. These analyses were con-
ducted for the entire sample, and also strati-
ﬁed by race/ethnicity and age.
Linear regression analyses were performed
with HOMA (log-transformed) and waist cir-
cumference as outcome variables. Because sev-
eral phthalate metabolites are strongly
correlated, each urinary phthalate metabolite
was examined separately. Phthalate metabolite
concentrations were log-transformed to nor-
malize the data. Categorical analyses by expo-
sure quintiles were also performed.
We conducted crude analyses and two
adjusted analyses for each phthalate. Adjusted
model 1 includes covariates discussed below.
Adjusted model 2 includes these covariates,
plus GFR, ALT, and GGT. Model 1 was our
primary model because phthalates are known
to affect the liver (Bhattacharya et al. 2005;
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therefore, adjusting for liver function (model
2) could remove true effects. Model 2 is also
needed, however, because obesity can affect
liver function (Lawlor et al. 2005) and thus
alter phthalate metabolism. GFR had mini-
mal effect on results but was left in model 2
for completeness. 
Age and race/ethnicity are known con-
founders and were included in fully adjusted
models. Urine creatinine was included to cor-
rect for urine concentration, as recommended
by Barr et al. (2005). Because the relationship
between age and prevalence of metabolic syn-
drome (an outcome related to our outcomes)
appears curvilinear (Park et al. 2003), age2
was also included. Age, age2, urine creatinine,
and race/ethnicity were forced into all models
regardless of their influence on metabolite
regression coefﬁcients. Other covariates were
evaluated as possible confounders. 
Covariates whose removal caused metabo-
lite parameter estimates to change by ≥ 10%
were considered confounders and left in the
adjusted models (Greenland 1989). Food
intake (total fat and calories), serum cotinine,
and activity measures were confounders for
two or more metabolites, and were therefore
included as covariates. Family history of dia-
betes and poverty income ratio were not
important confounders and had many miss-
ing values; thus they were omitted. The sam-
ple size for the full regression model was
reduced by 11% for waist circumference and
4.5% for insulin resistance due to missing
data for one or more covariates.
To assess the contribution of phthalate
metabolites to the model fit, the percent
variation in the outcome measures explained
by each metabolite was calculated by comput-
ing the difference in adjusted R2 between the
full model with and without that metabolite.
To convert regression coefﬁcients to clini-
cally interpretable measures, we first com-
puted the absolute change in waist
circumference and log HOMA represented by
an increase in the significant (p ≤ 0.05) log
phthalate metabolites from the 10th to 90th
percentiles, then calculated this increase in
waist circumference and HOMA as a percent
of their medians:
[2]
[3]
where β is the regression coefﬁcient for each
individual metabolite.
We used SAS, version 9.1 (SAS Institute,
Cary, NC) for all statistical analyses.
Appropriate weight variables were used to
account for oversampling of special demo-
graphic groups in NHANES, and sampling
cluster variables were used for its complex
sampling design. Phthalate subsample weight
variables were used for both waist circumfer-
ence and HOMA analyses. Because we exam-
ined only the adult male subpopulation in the
NHANES data, we used subpopulation
methods as described by Graubard and Korn
(1996).
The use of weights associated with indi-
vidual NHANES subsamples may be inaccu-
rate when two subsamples that do not
completely overlap are used simultaneously
in an analysis (NCHS 2006a). Our waist cir-
cumference analyses used only one subsample
(phthalates) and are unaffected; however,
HOMA analyses used both fasting and
phthalate subsamples, which only overlap by
50%. Consequently, the use of phthalate
weights in our HOMA analyses could affect
validity of these ﬁndings. Nevertheless, use of
fasting subsample weights, phthalate weights,
and no weights did not substantially alter our
interpretation of the HOMA results, which
also demonstrated similar patterns as our
Percent change in HOMA (at median)
l
=
× exp β n nm e t a b o l i t e l nm e t a b o l i t e 90th percentile 1 () − 0 0th percentile
median HOMA
() ⎡ ⎣ ⎤ ⎦ {}
Percent change in waist circumference (at me edian)
ln metabolite l 90th percentile
=
× () − β n nm e t a b o l i t e
median wai
10th percentile () ⎡ ⎣ ⎤ ⎦
s st circumference
Stahlhut et al.
878 VOLUME 115 | NUMBER 6 | June 2007 • Environmental Health Perspectives
Table 1. Mean median phthalate serum metabolite concentrations (µg/g creatinine): NHANES 1999–2002.a
4-Year 2-Year
MBP MBzP MEHP MEP MEHHP MEOHP
No. Mean ± SE (median) Mean ± SE (median) Mean ± SE (median) Mean ± SE (median) No. Mean ± SE (median) Mean ± SE (median)
All 1,443 33.8 ± 1.6 (21.2) 29.4 ± 2.7 (14.2)  11 ± 1.3 (3.8) 771 ± 66.7 (188.1) 780 65.8 ± 7.9 (19.6) 38.7 ± 4.5 (13.2)
By age (years)
19–35 469 36.1 ± 2.9 (23.9) 35.7 ± 6.0 (17.0) 12.8 ± 2.2 (5.1) 699.2 ± 117.2 (212.4) 253 77.5 ± 18.2 (22.1) 45.8 ± 9.9 (15.6)
36–50 386 31.0 ± 2.1 (21.4) 25.0 ± 1.8 (14.9) 13.4 ± 2.7 (3.9) 672.1 ± 130.3 (173.5) 219 68.9 ± 12.7 (20.1) 39.3 ± 8.2 (13.2)
51–65 284 33.4 ± 3.2 (18.3) 25.1 ± 4.3 (11.8) 7.1 ± 1.3 (2.5) 1017.5 ± 160.8 (208.7) 160 52.8 ± 14.4 (16.3) 32.1 ± 7.7 (11.6)
66–80 231 37.9 ± 5.7 (18.4) 25.9 ± 4.3 (11.3) 5.9 ± 1.0 (2.2) 933.7 ± 182.7 (139.1) 118 42.8 ± 17.5 (11.5) 26.0 ± 8.8 (7.5)
≥ 81  73 24.2 ± 2.9 (19.0) 49.6 ± 31.9 (12.1) 3.7 ± 0.7 (2.4) 503.7 ± 180.9 (94.8) 30 20.3 ± 4.9 (13.2) 13.5 ± 3.3 (8.3)
By ethnicity
Mexican American 335 33.1 ± 4.1 (23.2) 24.3 ± 3.3 (12.7) 8.6 ± 1.1 (4.0) 717.0 ± 82.2 (259.6) 161 34.0 ± 7.7 (15.6) 20.6 ± 4.2 (10.8)
Other Hispanic 75 39.7 ± 6.9 (24.2) 29.3 ± 4.1 (13.8) 14.9 ± 4.5 (6.9) 1347.3 ± 338.0 (292.1) 35 48.8 ± 17.3 (25.3) 30.0 ± 10.5 (15.9)
White 717 32.0 ± 1.9 (19.0) 28.5 ± 3.3 (14.0) 10.9 ± 1.8 (3.3) 703.1 ± 72.9 (158.8) 415 70.2 ± 11.8 (19.5) 41.9 ± 6.3 (13.1)
Black 271 45.6 ± 4.4 (31.7) 44.0 ± 9.4 (19.9) 13.4 ± 3.0 (5.3) 1086.5 ± 177.1 (362.6) 150 83.0 ± 24.7 (32.1) 42.5 ± 9.0 (18.7)
Other/multiethnic 45 28.7 ± 3.9 (28.1) 18.8 ± 2.8 (11.9) 5.0 ± .8 (3.8) 295.8 ± 65.6 (84.6) 19 14.7 ± 3.4 (12.3) 9.7 ± 2.1 (9.2)
a2001–2002 only for MEHHP and MEOHP.
Table 2. Association between waist circumference, HOMA (ln), and selected phthalate metabolites (ln):
NHANES 1999–2002.
Crude analysis Adjusted model 1a Adjusted model 2b
Outcome β (SE) p-Value β (SE) p-Value β (SE) p-Value
Waist circumference
1999–2002 (n = 1,451 crude, 1,292 adjusted)
MBP 1.39 (0.51) 0.011 0.98 (0.50) 0.059 0.79 (0.47) 0.106
MBzP 1.18 (0.47) 0.017 1.29 (0.34) 0.001 1.09 (0.36) 0.005
MEHP 0.24 (0.40) 0.550 0.62 (0.44) 0.170 0.53 (0.42)  0.217
MEP 0.95 (0.32) 0.005 0.77 (0.29) 0.013 0.66 (0.31) 0.041
2001–2002 (n = 781 crude, 696 adjusted)
MEHHP 1.82 (0.58) 0.007 1.71 (0.56) 0.008 1.65 (0.50) 0.005
MEOHP 2.00 (0.63) 0.006 1.81 (0.60) 0.009 1.79 (0.55) 0.005
HOMA (ln)
1999–2002 (n = 651 crude, 622 adjusted)
MBP 0.061 (0.024) 0.016 0.064 (0.024) 0.011 0.043 (0.023) 0.081
MBzP 0.059 (0.027) 0.037 0.079 (0.023) 0.002 0.061 (0.022) 0.009
MEHP 0.035 (0.023) 0.143 0.031 (0.025) 0.225 0.016 (0.024) 0.526
MEP 0.067 (0.021) 0.004 0.056 (0.020) 0.008 0.044 (0.021)  0.045
2001–2002 (n = 344 crude, 327 adjusted)
MEHHP 0.054 (0.029) 0.078 0.055 (0.028) 0.064 0.038 (0.023) 0.126
MEOHP 0.066 (0.031) 0.052 0.060 (0.032) 0.076 0.044 (0.027) 0.125
aAdjusted for age, age2, race/ethnicity, total fat and calorie intake, physical activity level, smoking exposure, and urine
creatinine. bAdjusted for model 1 covariates plus GFR, ALT, and GGT.waist circumference analyses. This suggests that
the use of two partially overlapping subsamples
did not signiﬁcantly impact our ﬁndings.
Results
Table 1 shows the median and mean phtha-
late levels in the U.S. population, overall and
stratiﬁed by age and race/ethnicity. Exposure
levels vary widely by phthalate metabolite,
with MEHP having the lowest concentration
among the six we analyzed, and MEP the
highest. Concentrations varied somewhat by
age, with greater median levels usually found
in younger age groups. For all phthalate
metabolites except MEHP, > 95% of subjects
were at ≥ LOD; for MEHP, 80% of subjects
were ≥ LOD. 
Concentrations also varied by race/ethnic-
ity. Blacks had higher levels of exposure than
whites and Mexican Americans for all phtha-
late metabolites. Mexican Americans had
somewhat higher levels than whites for MBP,
MEP, and MEHP.
Table 2 shows the regression results for
crude analysis (adjusting only for urinary
creatinine) and fully adjusted models. In the
adjusted model 1, increasing concentrations
of MBzP, MEHHP, and MEOHP were sta-
tistically significantly associated with greater
waist circumference, whereas concentrations
of MBP, MBzP, and MEP were signiﬁcantly
associated with increased log HOMA.
Adjusted model 2, which adjusted for renal
and hepatic function, showed declines in
parameter estimates, but all signiﬁcant results
remained so except HOMA-MBP.
Adjusted model 1 HOMA results gave
similar parameter estimates whether calculated
with phthalate or fasting subsample weights
(< 5% difference for analyses with signiﬁcant
p-values). For further verification, an
unweighted HOMA analysis was also con-
ducted (data not shown) with somewhat larger
changes in parameter estimates. However,
MBP, MEP, and MBzP were still signiﬁcantly
associated and MEHP was again not signifi-
cant. MEHHP and MEOHP gained signifi-
cance in the unweighted analysis.
Categorical dose–response analyses
demonstrated that the assumption of linearity
was not strongly violated, although the curves
appeared to level off, or perhaps decline, at
higher metabolite concentrations (Figure 1).
The contribution of phthalate metabolites
to model ﬁt is displayed in Table 3. Adjusted
R2 of the full model ranged from 15 to 20%
for both outcome measures. The addition of
significant phthalate metabolites explained
0.4–2.1% of outcome variability. Compared
with the overall explanatory power of the full
model, individual metabolites contributed
between 2.5 and 10.1% of the model ﬁt.
To convert regression coefﬁcients to clini-
cally interpretable measures, we computed the
Phthalates, waist circumference, and insulin resistance
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Figure 1. Fully-adjusted associations (adjusted model 1) between changes in outcomes and exposure
quintiles (quintile 1 is reference) for metabolites with significant/near-significant (p ≤ 0.10) continuous
regression coefﬁcients. Error bars indicate 95% conﬁdence intervals.
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represented by an increase in significant
phthalate metabolites from the 10th to 90th
percentiles in adjusted model 1. Waist cir-
cumference increased 3.9–7.8 cm (4.0–8.0%
of the 97.0-cm median) for four significant
metabolites: MEP (3.9 cm), MBzP (5.8 cm),
MEHHP (7.3 cm), and MEOHP (7.8 cm).
HOMA (at the 2.50 median) increased
1.3–1.4 (52–57% of median) in association
with three metabolites: MBP (1.3), MEP
(1.3), and MBzP (1.4).
Discussion
Obesity, insulin resistance, and diabetes have
increased substantially in prevalence over the
past three decades. Many plausible causes have
been described, such as perinatal exposures,
reduced physical activity, food marketing
strategies, poor city planning, and thrifty genes
(Ebbeling et al. 2002). However, if bioavailable
testosterone levels in American men have
declined considerably in recent years, as
recently reported by Travison et al. (2007),
then hypoandrogenism could be another con-
tributor to the epidemic of obesity and related
disorders. Hormonally active agents such as
phthalates could be one source of this decline
in testosterone level or, perhaps independently,
to a decline in androgen function.
In the present study, we found that the
log-transformed concentrations of several
phthalate metabolites were positively and sig-
nificantly correlated with abdominal obesity
(MBzP, MEHHP, MEOHP, MEP) and
insulin resistance (MBP, MBzP, MEP) in adult
U.S. males. Categorical analysis of these
metabolites by exposure quintiles yielded dose–
response curves consistent with this interpreta-
tion. Although wide conﬁdence intervals pre-
clude strong assertions, the HOMA analyses
curves suggest the inverted-U shaped, non-
monotonic dose–response sometimes seen with
hormonally active agents, including phthalates
(Andrade et al. 2006; Lehmann et al. 2004;
Takano et al. 2006; Welshons et al. 2003).
Adjustment for renal function had mini-
mal effect. Adjustment for liver function mod-
erated most associations but only eliminated
statistical significance for HOMA-MBP.
Whether this adjustment for liver function was
entirely appropriate is unclear, however.
Adjustment could be appropriate because obe-
sity can affect liver function, and thus may
alter phthalate metabolism. Conversely, adjust-
ing for liver function could falsely attenuate
real effects if phthalate exposure was partially
responsible for elevation of liver enzymes.
Among the DEHP metabolites available,
MEHP showed substantially weaker associa-
tions compared with the oxidative metabo-
lites MEHHP and MEOHP. This was not
unexpected because a recent study showed
MEHHP and MEOHP more active in ani-
mal models than MEHP (Stroheker et al.
2005). Further, MEHP has a shorter serum
half-life than these other DEHP metabolites,
thus reducing the correlation of MEHP
measurements with DEHP exposure (Koch
et al. 2005). 
To our knowledge, ours is the ﬁrst human
study to examine associations between phtha-
late metabolites and either abdominal obesity
or insulin resistance. In one animal study,
however, female rats exposed to DEHP were
found to have increased serum glucose and
decreased insulin, as well as thyroid and
adrenocortical dysfunction (Gayathri et al.
2004). However, the decreased insulin in that
study points to impaired beta cell function in
the pancreas, as found in type 1 diabetes or
later in the course of type 2 diabetes.
Like our study, others have found associa-
tions with outcomes that might follow from
antiandrogenic effects of MBP (Duty et al.
2003; Hauser et al. 2006; Main et al. 2006;
Swan et al. 2005) and MEP (Jönsson et al.
2005; Main et al. 2006; Swan et al. 2005),
and found no association with MEHP (Duty
et al. 2003; Hauser et al. 2006; Jönsson et al.
2005; Main et al. 2006; Swan et al. 2005).
Results for MBzP, MEHHP, and MEOHP
were less consistent. Assuming these associa-
tions represent true effects, differences
between our results and others could be due to
our larger sample sizes and increased power.
Phthalates might also affect adult males differ-
ently than fetuses, or they may interact
directly with energy balance or glucose
metabolism pathways in addition to anti-
androgenic effects. 
In our study, individual phthalate expo-
sures only explained ≤ 2.1% of the variability
of our outcomes (abdominal obesity and
insulin resistance). The full model, however,
explained only 15–20%, despite including the
well-accepted covariates of age, race/ethnicity,
fat and calorie intake, activity levels, and smok-
ing. In part, this demonstrates the difﬁculty of
predicting the presence of this complex, multi-
factorial clinical syndrome. In addition,
humans are exposed to multiple phthalates
simultaneously and in combination with other
potential environmental toxicants that may
add together to produce adverse effects. For
example, PCBs, dioxins, and organochlorine
pesticides have also been associated with dia-
betes prevalence in adult humans (Lee et al.
2006; Rylander et al. 2005). Combinations of
phthalates and other potential antiandrogens
have been shown in animal models to act in a
dose-additive manner (Gray et al. 2006;
Hotchkiss et al. 2004); in humans, Hauser
et al. (2005) found greater than additive effects
between MBP and PCB-153 on semen quality.
Although individual phthalate exposures in
humans are generally asserted to be below the
no observed effect level (NOEL), combina-
tions of man-made estrogenic chemicals, indi-
vidually below NOEL concentrations, have
been shown to exert considerable effect in a
yeast reporter gene assay using the human
estrogen receptor-α (Rajapakse et al. 2002). 
Estrogenic exposures might also add to
antiandrogenic exposures; some authors have
found the estradiol/testosterone (total) ratio
correlated more strongly with fasting glucose
and insulin than testosterone (free or total) or
estradiol alone (Phillips et al. 2003). Among
xenoestrogens, bisphenol A (currently unmea-
sured in NHANES) would be important to
investigate because it has recently been shown
to affect insulin production in mouse pancre-
atic beta cells in a manner similar to that of
estrogen (Alonso-Magdalena et al. 2006).
Our findings should be considered in
light of several important limitations. First, as
a cross-sectional study, this design cannot
examine changes over time. Second, HOMA
is a static measure of insulin resistance, unlike
the hyperinsulinemic–euglycemic clamp,
which limits its ability to detect abnormalities
in insulin secretion or peripheral glucose dis-
posal. This may have reduced our ability to
observe associations. Third, NHANES
1999–2002 contains no measures of sex hor-
mones, gonadotropins, or sex hormone-bind-
ing globulin in men, which limits our ability
to examine the mechanism of action proposed
in this study. Fourth, our HOMA analyses
are less generalizable to the population
because specially calculated sample weights
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Table 3. Outcome variation explained by and contribution to fit of phthalate metabolites significantly
(p ≤ 0.05) associated with one or both outcome measures (adjusted model 1).
Adj R2 of full model Adj R2 of full model Outcome variation  Model contribution 
with metabolite without metabolite explained by metabolite (%)a of metabolite (%)b
Waist circumference
MBzP 0.1587 0.1517 0.7 4.4
MEHHP 0.2042 0.1837 2.1 10.0
MEOHP 0.2043 0.1837 2.1 10.1
MEP 0.1556 0.1517 0.4 2.5
HOMA (ln)
MBP 0.1650 0.1575 0.8 4.5
MBzP 0.1748 0.1575 1.7 9.9
MEP 0.1727 0.1575 1.5 8.8
Adj, adjusted. 
a(R2
with metabolite – R2
without metabolite) × 100%. b[(R2
with metabolite – R2
without metabolite)/R2
with metabolite] × 100%.for the combined use of phthalate and fasting
subsamples are not available.
Fifth, our study was restricted to adult
males. Children and adolescents were
excluded from our study because fasting glu-
cose and insulin were not available in
NHANES 1999–2002 for subjects < 12 years
of age, and because in adolescents, hormone
levels vary greatly with stage of puberty.
Women were excluded due to the high degree
of premenopausal fluctuations in sex hor-
mones and the change in risk profile at
menopause. Also, women appear to respond
differently than men to low testosterone levels;
in women, low testosterone has been associ-
ated with reduced prevalence of obesity,
insulin resistance, and diabetes (Ding et al.
2006; Kalish et al. 2003; Oh et al. 2002). An
analysis of the adult women in this data set
indeed gave dissimilar results from men
(results not shown) and deserves further study. 
Sixth, the one-time spot urine samples
used in this study are limited measures of
long-term exposure to phthalates. If phthalates
are exerting antiandrogenic effects, one might
expect this effect to manifest over months to
years. No study has yet examined the correla-
tion between a spot urine phthalate measure-
ment and year-long exposure patterns. Hauser
et al. (2004b), however, found that a single
spot urine predicted the highest tercile of
phthalate exposure over 3 months with sensi-
tivities from 0.56 to 0.67 and specificities
from 0.83 to 0.87 among the phthalates in
our study. Hauser et al. also noted that urine
creatinine may not be the best way to correct
for variation in urine dilution, and that spe-
ciﬁc gravity (unavailable in NHANES) may be
a better approach. These flaws in exposure
classification also reduced our ability to
observe associations.
Seventh, people with obesity or insulin
resistance may be exposed to more phthalates
than people who do not have these conditions.
A few Food and Drug Administration–licensed
medications incorporate phthalates to modify
drug delivery (Schettler 2006), and this expo-
sure can sometimes be quite large (Hauser
et al. 2004a). Because people with disease are
also more likely to take medications, some of
the associations we have observed, particularly
with MBP and MEP (metabolites of DBP and
diethyl phthalate), may be falsely strengthened
through reverse causality. Adjustment for this
possible confounder would be difﬁcult, how-
ever. Phthalates are considered inert ingredi-
ents, and we are not aware of a comprehensive
database of inert ingredients for prescription
and over-the-counter medications, herbals, and
vitamins.
The present study has several important
strengths, based primarily on strengths of
NHANES data. Our sample was large,
nationally representative, and multiethnic.
Biomarkers were used for both exposures and
outcomes, and a number of relevant covariates
could be controlled.
Although we based our study on the
premise that phthalates are acting as anti-
androgens, the relationships between phtha-
late metabolites, abdominal obesity, and
insulin resistance may be complicated by
other mechanisms. For example, phthalates
can act as thyroid hormone receptor antago-
nists (Sugiyama et al. 2005). Some phthalate
metabolites are also known to interact with
peroxisome proliferator–activated receptors
(PPARs), which are not only important regu-
lators of lipid and glucose homeostasis (Evans
et al. 2004) but also mediate some effects of
phthalates on testicular and hepatic function
(Corton and Lapinskas 2005; Lapinskas et al.
2005). Activation of PPARs appear to have
generally beneficial effects on lipid and glu-
cose homeostasis, though medications that
activate PPARγ improve insulin sensitivity
while simultaneously increasing nonvisceral
fat mass (Semple et al. 2006). 
Several research paths would help deter-
mine the importance of our ﬁndings. Animal
studies conducted in human exposure ranges,
as well as human cross-sectional studies, could
explore the capacity of combinations of hor-
monally active agents to create metabolic dis-
turbances such as those we have examined
here. Studies similar to ours could be extended
to women, children, and adolescents, or to
related conditions such as metabolic syndrome.
Measurement of sex hormones, unavailable for
males in NHANES 1999–2002, might suggest
possible mechanisms. Examination of lipid
effects could help tease out PPAR contribu-
tions. Ultimately, longitudinal studies will be
required to provide more deﬁnitive answers.
In conclusion, in this large national cross-
sectional sample, several phthalate metabolites
showed statistically signiﬁcant positive corre-
lations with abdominal obesity and insulin
resistance in adult U.S. males. If conﬁrmed by
longitudinal studies, these associations would
suggest that phthalates, a widely used family
of chemicals, may contribute to the preva-
lence of obesity, insulin resistance, and related
clinical disorders. Because phthalates are
rapidly metabolized, unlike PCBs and other
persistent organic contaminants, such conﬁr-
mation could prompt effective actions to
reduce phthalate exposure in the population. 
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